LAVA therapeutics is a Dutch-American biotech that originated from Amsterdam UMC, Cancer Center Amsterdam to advance the development of a new immunotherapeutic strategy against cancer.
Under LAVA`s leadership, which includes scientific founder, chief scientific officer and Cancer Center Amsterdam medical oncologist Hans van der Vliet, the company is embarking on clinical trials to determine whether antibodies generated in llamas will be effective in activating patient’s gamma delta T-cells to destroy distinct cancers. To drive the development of LAVA`s pipeline of bispecific antibody drugs , LAVA Therapeutics successfully raised over 100 million dollars by selling shares on the Nasdaq Global Select Market since March 25, 2021. The company is trading on Nasdaq under the symbol ‘LVTX’.
For more information, see Link, our previous news items and the following pdf documents:
